U.S. markets open in 9 hours 16 minutes

Insulet Corporation (PODD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
289.20-1.40 (-0.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close290.60
Bid235.00 x 1100
Ask310.00 x 900
Day's Range286.99 - 291.69
52 Week Range214.93 - 309.99
Avg. Volume343,636
Market Cap19.918B
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.47
Earnings DateNov 02, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est290.41
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-35% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Insulet Corporation
    Analyst Report: Insulet CorporationInsulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 150,000 insulin-dependent diabetics are using it worldwide.
    Fair Value
    Economic Moat
    11 days agoMorningstar
View more
  • Zacks

    Here's Why You Should Retain Insulet (PODD) Stock for Now

    Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).

  • Motley Fool

    5 Top Stocks for September

    If the September Effect hits us again this year, our contributors have five stocks to suggest that you could pick up at a discount: Insulet (NASDAQ: PODD), Amazon (NASDAQ: AMZN), Shopify (NYSE: SHOP), Cresco Labs (OTC: CRLBF), and PubMatic (NASDAQ: PUBM). Medtronic and Tandem Diabetes were the first companies to offer next-generation, automated insulin delivery systems, but stiff competition from Insulet's Omnipod 5 could be coming soon.

  • Zacks

    Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

    Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.